New hope for chronic hives: Long-Term drug safety trial underway

NCT ID NCT06736262

First seen Mar 05, 2026 · Last updated Apr 25, 2026 · Updated 4 times

Summary

This study looks at the long-term safety of a drug called briquilimab for people with chronic hives (urticaria). It includes 67 adults who already took part in a previous briquilimab study. Researchers will track side effects and how well the drug controls hives over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for URTICARIA CHRONIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Investigative Site 101

    Baltimore, Maryland, 21224, United States

  • Investigative Site 103

    Cincinnati, Ohio, 45236, United States

  • Investigative Site 105

    San Diego, California, 92123, United States

  • Investigative Site 108

    Little Rock, Arkansas, 72205, United States

  • Investigative Site 109

    Boise, Idaho, 83706, United States

  • Investigative Site 110

    Indianapolis, Indiana, 46250, United States

  • Investigative Site 111

    Murray, Utah, 84107, United States

  • Investigative Site 115

    Seattle, Washington, 98101, United States

  • Investigative Site 116

    Tampa, Florida, 33613, United States

  • Investigative Site 118

    Birmingham, Alabama, 35244, United States

  • Investigative Site 121

    White Marsh, Maryland, 21162, United States

  • Investigative Site 123

    Lafayette, Louisiana, 70508, United States

  • Investigative Site 124

    Normal, Illinois, 61761, United States

  • Investigative Site 201

    Berlin, 12203, Germany

  • Investigative Site 202

    Marburg, Hesse, 35043, Germany

  • Investigative Site 204

    Münster, North Rhine-Westphalia, 48149, Germany

  • Investigative Site 206

    Lübeck, Schleswig-Holstein, 23538, Germany

  • Investigative Site 209

    Dresden, Saxony, 01307, Germany

  • Investigative Site 210

    München, Bavaria, 80802, Germany

Conditions

Explore the condition pages connected to this study.